{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
amphotericin b
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Targets:
Conditions:
Dicarbine is an orally active drug approved in Russia under the trade name Карбидин, is used for the treatment patients with schizophrenia and alcoholic psychosis. This drug blocks dopamine receptors in various brain parts, which leads to a reduction in the productive symptoms of psychosis: delusions and hallucinations.
Status:
Investigational
Source:
NCT00766324: Phase 2 Interventional Completed Metastatic Hormone Refractory Prostate Cancer
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Danusertib is a serine/threonine kinase inhibitor of multiple kinases, including aurora-A, B, and C. It also inhibits several cancer related tyrosine kinases as well as Abl, Trk-a, fibroblast growth receptor-1 and Ret. Danusertib is in phase II trials for the treatment of solid tumours, prostate cancer and chronic myeloid leukemia (CML). The most frequently reported side effects were neutropenia, nausea, anorexia, fatigue, and diarrhea.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Flutroline, an antipsychotic drug that was studied to treat patients with schizophrenia. Clinical trials have shown that the drug was a safe, effective, and 20 mg and above offered the best potential for optimal clinical effectiveness. However, information about the further development of this drug is not available.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Indocate is indole derivative and monoamine oxidase inhibitor with peripheral antiserotonin properties.
Status:
Investigational
Source:
NCT02364206: Phase 1/Phase 2 Interventional Completed Adult Glioblastoma
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ralimetinib (LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the α- and β-isoforms of p38 mitogen-activated protein kinase. LY2228820 produced significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast). Eli Lilly is developing ralimetinib for the treatment of cancer.
Status:
Investigational
Source:
NCT02685137: Phase 3 Interventional Completed Nutritional and Metabolic Diseases
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Stannsoporfin is a mesoporphyrin derivative patented by Rockefeller University as competitive heme oxygenase (HO) inhibitor for the prevention of hyperbilirubinemia in infants at risk of developing jaundice. Parenteral administration of Stannsoporfin has been shown to suppress or moderate jaundice in a wide variety of experimental and naturally occurring forms of hyperbilirubinemia in animals and man. Stannsoporfin is rapidly cleared from the plasma in animals, in adult humans, and in newborn infants and may inhibit competitive heme oxygenase for prolonged periods. The Stannsoporfin decreases the production of carbon monoxide from heme and increases the biliary excretion of unmetabolized heme but has no effect on the metabolic disposition of preformed bilirubin.
Class (Stereo):
CHEMICAL (RACEMIC)
Etazepine (5,6-dihydro-5-methyl-11H-11-ethoxy-dibenzo[b,e]azepin-6-one) demonstrates anticonvulsant activity in rodents. Etazepine seems to exert its anticonvulsant effects by activating the GABAergic system.
Status:
Investigational
Source:
NCT01429623: Phase 2 Interventional Completed Mild Cognitive Impairment
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LADOSTIGIL, a rasagiline derivative, is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor with neuroprotective properties. It also acts as an irreversible brain monoamine oxidases inhibitor. It is under development for the treatment of neurodegenerative disorders like dementia and Alzheimer's disease.
Class (Stereo):
CHEMICAL (RACEMIC)
Fosquidone (also known as GR63178A), a pentacyclic pyrroloquinone that was developed as an anticancer agent. Fosquidone participated in phase II clinical trial for the treatment of patients with colorectal, renal and non-small cell lung cancer. However, the drug didn’t show significant antitumor activity. The further development of this drug was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gomisin A (BESIGOMSIN/GA) one of the major dibenzocyclooctadiene lignans isolated from Schisandra chinensis Baill, has proved to possess a variety of pharmacological effects. It has been found to promote hepatocyte growth factor, limit lipid peroxidation, and inhibit apoptosis in acute hepatic injury animal models. Besigomsine also acts as an anti-inflammatory by preventing the release of arachidonic acid in macrophages in vitro. Laboratory evidence suggests that Besigomsine may have anticarcinogenic effects. Chronic administration of Gomisin A had an antihypertensive effect in AngII-induced hypertensive mice. Gomisin A may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. Also it induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway.
